107 related articles for article (PubMed ID: 6344993)
1. The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.
Redmond C; Fisher B; Wieand HS
Cancer Treat Rep; 1983 Jun; 67(6):519-26. PubMed ID: 6344993
[No Abstract] [Full Text] [Related]
2. Comment on "The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival".
Bonadonna G; Valagussa P
Cancer Treat Rep; 1983 Jun; 67(6):527-9. PubMed ID: 6688038
[No Abstract] [Full Text] [Related]
3. Evolving concepts in the systemic adjuvant treatment of breast cancer.
Bonadonna G
Cancer Res; 1992 Apr; 52(8):2127-37. PubMed ID: 1559216
[No Abstract] [Full Text] [Related]
4. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
Albain KS
J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
[No Abstract] [Full Text] [Related]
5. Adjuvant systemic therapy in primary breast cancer.
Mouridsen HT; Palshof T
Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
[No Abstract] [Full Text] [Related]
6. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
[TBL] [Abstract][Full Text] [Related]
7. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
8. Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Kümmel S; Krocker J; Kohls A; Breitbach GP; Morack G; Budner M; Blohmer JU; Lichtenegger W; Elling D
Crit Rev Oncol Hematol; 2006 May; 58(2):166-75. PubMed ID: 16387512
[TBL] [Abstract][Full Text] [Related]
9. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
Ejlertsen B; Mouridsen HT; Jensen MB
Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant combination chemotherapy for operable breast cancer. Trials in progress at the Istituto Nazionale Tumori of Milan.
Bonadonna G; Rossi A; Tancini G; Bajetta E; Marchini S; Brambilla C; Tesoro Tess JD; Valagussa P; Banfi A; Veronesi U
Cancer Treat Rep; 1981; 65 Suppl 1():61-5. PubMed ID: 7034930
[TBL] [Abstract][Full Text] [Related]
12. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
[TBL] [Abstract][Full Text] [Related]
13. Occasional notes. The management of early breast cancer.
Canellos GP; Hellman S; Veronesi U
N Engl J Med; 1982 Jun; 306(23):1430-2. PubMed ID: 7043266
[No Abstract] [Full Text] [Related]
14. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
Mayers C; Panzarella T; Tannock IF
Cancer; 2001 Jun; 91(12):2246-57. PubMed ID: 11413512
[TBL] [Abstract][Full Text] [Related]
15. Poor outcome of patients with resectable breast cancer receiving adjuvant high-dose sequential chemotherapy following preoperative treatment.
Zambelli A; Da Prada GA; Pedrazzoli P; Ponchio L; Robustelli della Cuna G
Anticancer Res; 1999; 19(3B):2373-6. PubMed ID: 10472359
[TBL] [Abstract][Full Text] [Related]
16. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant endocrine therapy and chemotherapy of breast cancer (author's transl)].
Heuson JC; Paridaens R
Rev Med Brux; 1982 Apr; 3(4):209-16. PubMed ID: 7046007
[No Abstract] [Full Text] [Related]
18. [Clinical analysis of resectable breast cancer: a report of 6 263 cases].
Yang MT; Rong TH; Huang ZF; Zeng CG; Long H; Fu JH; Lin P; Wang X; Wang SY; Wang X; Tang J
Ai Zheng; 2005 Mar; 24(3):327-31. PubMed ID: 15757535
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Ost E; Illiger HJ
Strahlenther Onkol; 2002 Jan; 178(1):54-5. PubMed ID: 11977396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
